NasdaqCM:PRPO

Stock Analysis Report

Executive Summary

Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market.

Snowflake

Fundamentals

Limited growth and overvalued.

Risks

  • Precipio has significant price volatility in the past 3 months.
  • Precipio is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Precipio's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.0%

PRPO

-0.04%

US Healthcare

-0.6%

US Market


1 Year Return

-60.8%

PRPO

-9.1%

US Healthcare

0.6%

US Market

PRPO underperformed the Healthcare industry which returned -9% over the past year.

PRPO underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

PRPOIndustryMarket
7 Day-2.0%-0.04%-0.6%
30 Day-9.2%-0.5%2.2%
90 Day-17.9%-1.6%1.1%
1 Year-60.8%-60.8%-7.7%-9.1%2.9%0.6%
3 Yearn/a29.6%24.3%44.6%35.2%
5 Yearn/a66.1%56.2%61.9%44.2%

Price Volatility Vs. Market

How volatile is Precipio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 year ago | Simply Wall St

Why Precipio Inc's (NASDAQ:PRPO) Investor Composition Impacts Your Returns

Valuation

Is Precipio undervalued based on future cash flows and its price relative to the stock market?

1.04x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Precipio to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Precipio to establish if it is available at substantial discount.


Price Based on Earnings

Precipio is loss making, we can't compare its value to the US Healthcare industry average.

Precipio is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Precipio, we can't assess if its growth is good value.


Price Based on Value of Assets

Precipio is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Precipio expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

62.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Precipio's revenue is expected to grow significantly at over 20% yearly.

Precipio is not considered high growth as it is expected to be loss making for the next 1-3 years.

Precipio's revenue growth is expected to exceed the United States of America market average.

Unable to compare Precipio's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Precipio's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Precipio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Precipio performed over the past 5 years?

-36.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Precipio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Precipio's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Precipio's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Precipio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Precipio has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Precipio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Precipio's financial position?


Financial Position Analysis

Precipio's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Precipio's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Precipio's level of debt (2.6%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Precipio's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 6.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Precipio has less than a year of cash runway based on current free cash flow.

Precipio has less than a year of cash runway if free cash flow continues to grow at historical rates of 56.3% each year.


Next Steps

Dividend

What is Precipio's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Precipio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Precipio's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Precipio has not reported any payouts.

Unable to verify if Precipio's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Precipio has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Precipio's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Ilan Danieli (47yo)

2.3yrs

Tenure

US$913,797

Compensation

Mr. Ilan Danieli is the Founder of Precipio, Inc. and has been its Chief Executive Officer since June 29, 2017 and serves as its President and Director. Mr. Danieli has over 15 years managing small and me ...


CEO Compensation Analysis

Ilan's remuneration is higher than average for companies of similar size in United States of America.

Ilan's compensation has increased whilst company is loss making.


Management Age and Tenure

2.3yrs

Average Tenure

47yo

Average Age

The tenure for the Precipio management team is about average.


Board Age and Tenure

2.0yrs

Average Tenure

58.5yo

Average Age

The average tenure for the Precipio board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Precipio individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$2,49005 Sep 19
Ilan Danieli
EntityIndividual
Role
Chief Executive Officer
Founder
Shares965
Max PriceUS$2.58
BuyUS$2,47510 Jun 19
Ilan Danieli
EntityIndividual
Role
Chief Executive Officer
Founder
Shares586
Max PriceUS$4.22

Ownership Breakdown


Management Team

  • Steve Miller (53yo)

    Chief Commercial Officer

    • Tenure: 2.3yrs
  • Carl Iberger (66yo)

    CFO & Secretary

    • Tenure: 2.9yrs
    • Compensation: US$403.16k
  • Ilan Danieli (47yo)

    Founder

    • Tenure: 2.3yrs
    • Compensation: US$913.80k
  • Ori Karev

    Chief Strategy Officer

    • Tenure: 0.4yrs
  • Ayman Mohamed (34yo)

    Senior VP of R&D and Laboratory Operations

    • Tenure: 2.3yrs
  • Doug Sites

    Vice President of Sales

    • Tenure: 1.7yrs
  • Ahmed Sabet (33yo)

    Chief Operating Officer

    • Tenure: 2.3yrs
    • Compensation: US$342.44k

Board Members

  • Kathy LaPorte (57yo)

    Non Executive Director

    • Tenure: 1.1yrs
    • Compensation: US$42.81k
  • Jeffrey Sklar (71yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Samuel Riccitelli (60yo)

    Chairman of the Board

    • Tenure: 1.8yrs
    • Compensation: US$114.58k
  • Doug Fisher (43yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$115.27k
  • Ilan Danieli (47yo)

    Founder

    • Tenure: 2.3yrs
    • Compensation: US$913.80k
  • David Cohen (60yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$100.58k
  • Jeff Cossman (72yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$112.58k
  • S. Hudnall

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mark Rimer (38yo)

    Director

    • Tenure: 7.5yrs
    • Compensation: US$109.58k
  • Mike Makrigiorgos

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Precipio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Precipio, Inc.
  • Ticker: PRPO
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$15.051m
  • Shares outstanding: 6.09m
  • Website: https://www.precipiodx.com

Number of Employees


Location

  • Precipio, Inc.
  • 4 Science Park
  • New Haven
  • Connecticut
  • 6511
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRPONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2017
TGKQDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2017

Biography

Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:22
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.